#United States #Pittsburgh #YORVIPATH® #Ascendis Pharma #PANTHERx

PANTHERx® Rare Partners with Ascendis Pharma for YORVIPATH®

In a significant move for the rare disease treatment landscape, PANTHERx® Rare, a leading specialty pharmacy known for its patient access initiatives, has announced its collaboration with Ascendis Pharma to distribute YORVIPATH® (palopegteriparatide). This FDA-approved medication is crucial in treating hypoparathyroidism, a rare endocrine disorder affecting approximately 70,000 adults in the United States.

Understanding Hypoparathyroidism

Hypoparathyroidism occurs when the body produces insufficient amounts of parathyroid hormone (PTH), leading to complications in calcium and phosphorus levels. A common cause is damage to the parathyroid glands during neck surgery, accounting for about 75% of cases. Other rare causes include genetic conditions and infiltration of the glands by various substances.

Patients suffering from chronic hypoparathyroidism often face numerous symptoms, including fatigue, muscle cramps, and neurological disturbances. Severe complications can arise, affecting renal function and cognitive abilities, making effective treatment essential. YORVIPATH® aims to provide consistent PTH exposure over 24 hours, ensuring better management of symptoms for patients.

PANTHERx® Rare: A Leader in Specialty Pharmacy

PANTHERx® Rare specializes in rare and orphan diseases. The pharmacy is committed to transforming the lives of its patients through innovative treatments and dedicated services. Recognized for its quality, it has received multiple accolades, including the ACHC Distinction in Orphan Drugs and the URAC Rare Disease Center of Excellence recognition.

Bansi Nagji, CEO of PANTHERx® Rare Pharmacy, expressed enthusiasm about the collaboration, saying, “We strive to be the catalyst that seamlessly delivers essential medications to individuals confronting rare conditions.” This partnership not only enhances medication availability but also promises to foster significant improvements in the quality of life for those affected by hypoparathyroidism.

The Broader Impact of Rare Disease Initiatives

The rise in FDA-approved treatments for rare diseases offers hope to millions. Currently, there are over 7,000 identified rare conditions, with more than 90% lacking approved treatments. Collaborations like PANTHERx® Rare’s with Ascendis Pharma highlight the importance of addressing these unmet medical needs, striving to provide solutions for patients in distress.

YORVIPATH® is already available in the European Union, UK, and European Economic Area, and its distribution across the United States will mark another critical step in providing healthcare solutions to this underserved population.

In conclusion, this partnership emphasizes not only the importance of specialized pharmacies but also the critical need for patient support in managing rare diseases. As PANTHERx® Rare continues to expand its outreach and resources, patients can look forward to enhanced accessibility to necessary treatments like YORVIPATH®.

References

• - Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020; 105(6): 1722-36. doi:10.1210/clinem/dgaa113
• - Hypoparathyroidism - Symptoms, Causes, Treatment | NORD. rarediseases.org. Retrieved from https://rarediseases.org/rare-diseases/hypoparathyroidism/#symptoms

For more information, contact [email protected]